Cargando…

MON-328 Disorders of Glucose Metabolism in Cushing Syndrome in Uzbekistan

Relevance. Cushing’s Syndrome (CS) is a serious risk factor for developing impaired glucose tolerance disorder (GTD) and a manifestation of secondary diabetes mellitus (DM). On the other hand, the development of impaired glucose metabolism affects not only the course but also the outcome of SC. More...

Descripción completa

Detalles Bibliográficos
Autores principales:	Narimova, Gulchekhra Djumaniyazovna, Khalimova, Zamira Yusufovna, Narimova, Malika Ikramovna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Neuroendocrinology and Pituitary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207992/ http://dx.doi.org/10.1210/jendso/bvaa046.1715

Ejemplares similares

MON-322 The Characteristic of Reproductive Disorders in Women with ACTH-Dependent Cushing Syndrome in the Republic of Uzbekistan (RUz) and Republic of Karakalpakstan (RKK)
por: Khalimova, Zamira Yusufovna, et al.
Publicado: (2020)

MON-299 Risk Factors of Re-Growth of Non-Functional Pituitary Adenomas
por: Khalimova, Zamira Yusufovna, et al.
Publicado: (2020)

MON-412 Subclinical Cushing's Disease and the Importance of Broad Differential Diagnoses
por: Walker, Michelle, et al.
Publicado: (2019)

MON-461 Drug Repurposing to Explore Novel Treatment for Cushing Disease
por: Zhang, Dongyun, et al.
Publicado: (2019)

MON-403 Osteoporosis: A Frequently Neglected Consequence of Cushing's Disease
por: Pedro, Jorge, et al.
Publicado: (2019)

MON-318 Acute, Life-Threatening and Perioperative Complications in Cushing’s Syndrome: Predictors and Outcomes
por: Schernthaner-Reiter, Marie Helene, et al.
Publicado: (2020)

MON-405 Cushing's Disease: An Oligosymptomatic Patient with ACTH-Secreting Pituitary Macroadenoma
por: Manrique Franco, Katty, et al.
Publicado: (2019)

MON-404 Reversible Dilated Cardiomyopathy in a Severe Case of Cushing’s Disease
por: Valente do Couto, Hugo, et al.
Publicado: (2019)

MON-321 AgRP and Food Cravings Decrease with Treatment of Cushing’s Disease
por: Haseltine, Katherine N, et al.
Publicado: (2020)

MON-LB078 Desmopressin Stimulated Salivary Cortisol as a Suplementary Tool in the Diagnosis of Cushing's Syndrome
por: Firme, Ricardo
Publicado: (2019)

MON-312 The Effects of Cabergoline in Pre-Surgical and Recurrence Periods of Cushing’s Disease Patients
por: Pereira, Ana Julia Garcia, et al.
Publicado: (2020)

MON-435 The Responsiveness To Ddavp Test Predicts Usp8 Mutation In Patients With Cushing's Disease
por: Shichi, Hiroki, et al.
Publicado: (2019)

MON-410 Ectopic ACTH- Secreting Tumor Causing Rapidly Progressive Cushing’s Syndrome Remains an Elusive Localization Diagnosis
por: Anaya Noubleau, Axa, et al.
Publicado: (2019)

MON-408 Development of Rapidly Progressive Cushing's Disease Following Pituitary Apoplexy Several Years Prior
por: Ortegon Zambrano, Pilar, et al.
Publicado: (2019)

MON-411 Psychological Disturbance And Weight Gain; Early Identification Of Cushing’S Disease In A Teenage Patient.
por: Hasan, Sana
Publicado: (2019)

MON-444 Defining Remission In Cushing Syndrome After Tumor Resection In Cases Of Non-suppressed Postoperative Serum Cortisol Levels
por: McGlotten, Raven, et al.
Publicado: (2019)

MON-LB51 Stimulation for Bilateral Inferior Petrosal Sinus Sampling May Be Unnecessary for Diagnosis of ACTH Dependent Cushing Syndrome
por: Builes-barrera, Carlos Alfonso, et al.
Publicado: (2020)

MON-329 Diagnostic Utility of Overnight High Dose Dexamethasone Suppression Test for Differentiating the Etiology of ACTH Dependent Cushing’s Syndrome
por: Yadav, Subhash B, et al.
Publicado: (2020)

MON-457 One in Five Patients Develop Multiple Hormone Deficiencies Following Radiotherapy for Acromegaly or Cushing's Disease
por: Shen, Angeline, et al.
Publicado: (2019)

MON-LB58 The Use of 11C Methionine PET CT In Localization of ACTH Dependent Cushing’s Disease
por: ElEbrashy, Shady Ibrahim, et al.
Publicado: (2020)

FRI328 Granulomatous Hypophysitis With Magnificent Response To Glucocorticoids
por: Rodriguez Caballero, Maria Galiana, et al.
Publicado: (2023)

MON-332 Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome (LOGICS): A Double-Blind, Placebo-Controlled, Withdrawal Study
por: Zacharieva, Sabina Z, et al.
Publicado: (2020)

MON-407 Tumor Control after Radiotherapy and Temozolomide in a Cushing's Disease Patient with Giant Aggressive Pituitary Tumor
por: Valente do Couto, Hugo, et al.
Publicado: (2019)

MON-295 Desmopressin Test in Silent Corticothoph Pituitary Adenomas, a Preliminary Study - a Comparison with Cushing Disease
por: Huayllas, Martha Katherine, et al.
Publicado: (2020)

MON-LB074 Ultrasonography May Reliably Assess Muscle Architecture in Patients with Cushing's Syndrome in Remission: Comparison with Gold-Standard Muscle MRI
por: Martel, Luciana, et al.
Publicado: (2019)

MON-LB073 The Serum Creatinine to Serum Cystatin C Ratio Is a Reliable Surrogate Marker of Sarcopenia in Patients with Cushing's Syndrome in Remission
por: Martel, Luciana, et al.
Publicado: (2019)

MON-445 Long-Term Results of an Ongoing Non-Interventional, Real-World Observational Study of Pasireotide SC in Cushing's Disease
por: Yuen, Kevin, et al.
Publicado: (2019)

MON-469 Pituitary Corticotroph Lesions: Clinical, Biochemical, and Pathological Characterization of Cushing Disease, Silent Corticotroph Adenomas, and Corticotroph Hyperplasia
por: Castlen, Joseph, et al.
Publicado: (2019)

MON-442 Evaluation of Copeptin as a Surrogate for AVP in the Diagnosis of Water Metabolism Disorders
por: McPhaul, Michael, et al.
Publicado: (2019)

MON-453 Endocrine, Bone, and Metabolic Disorders in Adults after Allogeneic Stem-Cell Transplant
por: Demeocq, Vianney, et al.
Publicado: (2019)

Hypercoagulability in ACTH-Dependent Cushing Syndrome
por: Singh Sumal, Amit Kartar, et al.
Publicado: (2021)

Occult Carcinoid Causes Cushing’s Syndrome
por: Meftali, Sabrina, et al.
Publicado: (2021)

MON-311 Glucose Metabolism in Acromegaly Patients Resistant to First Generation Somatostatin Receptor Ligands Treated with Pegvisomant And/Or Pasireotide Lar
por: Chiloiro, Sabrina, et al.
Publicado: (2020)

MON-413 First Reported Case of Combined High-Dose Mifepristone Therapy and Oral Contraceptive in Inducing Reversible Cholestatic Hepatitis in a Patient with Cushing Disease
por: Youssef, Nancy, et al.
Publicado: (2019)

MON-474 Dipeptidyl Peptidase-4 (DPP4) Inhibition Decreases Visceral Fat and Improves Glucose Metabolism in Overweight Women with Polycystic Ovarian Syndrome
por: Devin, Jessica, et al.
Publicado: (2019)

SAT-256 The Ever Confusing Cushing’s Work Up: Is It Real? Is It Pseudo Cushing’s’? Or Could It Be Factitious
por: Ghalib, Luma, et al.
Publicado: (2020)

MON-471 A New Look at the Endocrinology of Posttraumatic Stress Disorder (PTSD)
por: Chasalow, Fred, et al.
Publicado: (2019)

Long-Term Corticotroph Function Following Cure of Cushing’s Syndrome
por: Schernthaner-Reiter, Marie Helene, et al.
Publicado: (2021)

ODP328 Longitudinal Multidisciplinary Approach for Cabergoline-Resistant Aggressive Prolactinoma Complicated by Multiple Endocrine Neoplasia Type 1
por: Furusawa, Sho, et al.
Publicado: (2022)

MON-LB079 A Multicenter, Randomized, Open-Label, Phase IV Study Investigating Management of Pasireotide-Associated Hyperglycemia with Incretin-Based Therapy or Insulin in Patients with Acromegaly or Cushing's Disease (CD)
por: Samson, Susan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_76uina1q1uhg0ifle215rdi49k